Side by side
Consultation participation and their own register declarations, side by side. Counts, not judgments — participation is not influence.
Counts here are a floor, never a total: they cover the 583 consultation files tracked so far (42,224 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Company · Sweden
Industry association · Italy
Declared costs: €900K+ a year · in the register since 2009
Compulsory licensing of patents in crisis situations · Supplementary protection certificate for plant protection products. Recast
Register facts self-declared (snapshot 2 Sept 2026); cost bands are floors. Shared files are shared attention, not evidence of coordination.
Their opening passages on the files they share, verbatim and in filing order. We do not summarize, compare, or characterize positions — read them at source.
The Swedish Association of the Pharmaceutical Industry · filed 29 Apr 2022 · source
The significant investment in research and development (R & D) by several actors and for many years in new technologies, vaccines, therapeutic and other products, now available to deal with COVID-19, would not have existed without the current and robust EU IP system.
Filed in Swedish · English published by the European Commission
Confindustria · filed 18 Jul 2023 · source
Confindustria contributed and agrees with BusinessEurope's position paper on European Commission proposal for mandatory authorization for the crisis management. Confindustria, in line with European industry, expresses strong concern about the EC proposal, which risks weakening the European patent law system to the detriment of innovation and competitiveness in the Eurozone
Confindustria · filed 1 Apr 2022 · source
A centralized system for the grant and enforcement of a Unitary SPC (“uSPC”) through a single procedure, analogously with what is being achieved with the European Patent with Unitary Effect and Unified Patent Court ( EP-UE and UPC, respectively) is certainly a very desirable option with a view to creating a more predictable, less burdensome and cost-effective system for Europe.
The Swedish Association of the Pharmaceutical Industry · filed 5 Apr 2022 · source
The SPC is a very important intellectual property right for pharmaceutical companies, enabling innovation and the making available of new medicines. The positive effect of the SPC in this regard was confirmed by the Commission’s evaluation of the SPC legislation in 2020. In view of the above, Lif strongly believes that no changes should be made to the SPC itself or to related legislation (alt C2).
Filed in Swedish · English published by the European Commission
2 organizations on one sheet: every file each filed on, their register declarations, and a working link to each submission. Free: we ask for your name and email, and PolicySpeak may contact you about the product (privacy policy). The per-file record stays downloadable without signing up on each file’s page.